The Readout

The Readout By Damian Garde

A blow for blood plasma for Covid-19, an analog vaccine system, & a new podcast host

The Readout By Damian Garde

FDA takes on Covid-19 vaccines, long-awaited clarity for Biogen, & psilocybin’s Wall Street success

The Readout By Damian Garde

How CRISPR could benefit CAR-T, FDA tea leaves, & how to regulate AI

The Readout By Damian Garde

A milestone for Covid-19 vaccines, Hong Kong’s next big biotech IPO, & a third act for a Shkreli company

The Readout By Meghana Keshavan

Trump’s biotech endorsement, Intercept’s quiet disclosure, & an anti-climax for Amgen

The Readout By Damian Garde

Regeneron’s surreal week, Lilly’s Covid-19 data, & biotech’s silly season

The Readout By Meghana Keshavan

Tapping on the OWS brakes, U.S. insulin is pricy, & clinical trial limbo

The Readout By Damian Garde

Bristol Myers’ $13B bet, Amgen’s noisy silence, & the FDA’s willingness to say no

The Readout By Meghana Keshavan

Trump’s Covid-19 battle, a trial data attack, & boosting checkpoint inhibitors

The Readout By Meghana Keshavan

Trump tests positive for Covid-19, Congress probes biopharma, & Nobel predictions

The Readout By Damian Garde

Your guide to the rest of 2020, Celgene gets grilled, & Trump trusts pharma?

The Readout By Damian Garde

Regeneron’s Covid-19 drug shows early promise; will biotech’s diversity push continue post-pandemic?

The Readout By Meghana Keshavan

Novavax expands, diversifying trials, & Exact Sciences’ liquid biopsy boost

The Readout By Damian Garde

The fastest Covid-19 vaccine might not be best & familiar bad news in Alzheimer’s

The Readout By Damian Garde

J&J advances its Covid-19 vaccine, biotech’s high-risk lottery ticket, & ‘Vertex 3.0’

The Readout By Damian Garde

Regeneron’s ESMO coup, a CEO under house arrest, & Illumina’s pivot

The Readout By Meghana Keshavan

Tantalizing ESMO data, a “Trump card” pricing fail, & Genentech’s diverse Covid-19 trial

The Readout By Meghana Keshavan

Learning from Covid-19, tracking vaccine protocols, & gearing up for ESMO

The Readout By Damian Garde

Moderna’s next business move, Illumina’s reach for Grail, & Biogen’s patent peril

The Readout By Damian Garde

Lilly’s promising Covid-19 data, SPACs’ short shelf life, & AstraZeneca’s indefinite pause

The Readout By Damian Garde

Pfizer’s turnaround plan, a psychedelic biotech IPO, & Trump’s latest pricing gambit

The Readout By Meghana Keshavan

Gilead’s $21B buy, a CRISPR patent ruling, & Trump’s drug pricing EO

The Readout By Meghana Keshavan

JPM goes virtual, blood thinners for Covid-19, & Elizabeth Holmes’ surprising defense

The Readout By Meghana Keshavan

AstraZeneca halts Covid-19 study, Merck’s mediocre cough drug, & Corbus’ disappointment

The Readout By Meghana Keshavan

Most Read

Declining vaccine interest, Trump’s Covid-19 pivot, & squeezing fundraises

A J&J Covid-19 trial pause, aducanumab off-label, Moderna’s ever-wealthier execs

Merck’s BCG expansion, Vertex and Amgen strategies, & prepping vaccine cargo

Lilly’s Covid-19 trial pause, the importance of data monitors, & signs of SPAC softening

Merck vs. Pfizer, a Grail IPO, & why AZN halted that Covid-19 vaccine trial

Vertex stumbles, traders tune into talk radio, & pharma spends big in statehouses

Biogen’s FDA reckoning, pharma returns to D.C., & Inovio’s unwinding plans

Inside Operation Warp Speed, investor solidarity, & inside a vaccine approval

All Coverage

A blow for blood plasma for Covid-19, an analog vaccine system, & a new podcast host

FDA takes on Covid-19 vaccines, long-awaited clarity for Biogen, & psilocybin’s Wall Street success

How CRISPR could benefit CAR-T, FDA tea leaves, & how to regulate AI

A milestone for Covid-19 vaccines, Hong Kong’s next big biotech IPO, & a third act for a Shkreli company

Trump’s biotech endorsement, Intercept’s quiet disclosure, & an anti-climax for Amgen

Regeneron’s surreal week, Lilly’s Covid-19 data, & biotech’s silly season

Tapping on the OWS brakes, U.S. insulin is pricy, & clinical trial limbo

Bristol Myers’ $13B bet, Amgen’s noisy silence, & the FDA’s willingness to say no

Trump’s Covid-19 battle, a trial data attack, & boosting checkpoint inhibitors

Trump tests positive for Covid-19, Congress probes biopharma, & Nobel predictions

Your guide to the rest of 2020, Celgene gets grilled, & Trump trusts pharma?

Regeneron’s Covid-19 drug shows early promise; will biotech’s diversity push continue post-pandemic?

Novavax expands, diversifying trials, & Exact Sciences’ liquid biopsy boost

The fastest Covid-19 vaccine might not be best & familiar bad news in Alzheimer’s

J&J advances its Covid-19 vaccine, biotech’s high-risk lottery ticket, & ‘Vertex 3.0’

Regeneron’s ESMO coup, a CEO under house arrest, & Illumina’s pivot

Tantalizing ESMO data, a “Trump card” pricing fail, & Genentech’s diverse Covid-19 trial

Learning from Covid-19, tracking vaccine protocols, & gearing up for ESMO

Moderna’s next business move, Illumina’s reach for Grail, & Biogen’s patent peril

Lilly’s promising Covid-19 data, SPACs’ short shelf life, & AstraZeneca’s indefinite pause

Pfizer’s turnaround plan, a psychedelic biotech IPO, & Trump’s latest pricing gambit

Gilead’s $21B buy, a CRISPR patent ruling, & Trump’s drug pricing EO

JPM goes virtual, blood thinners for Covid-19, & Elizabeth Holmes’ surprising defense

AstraZeneca halts Covid-19 study, Merck’s mediocre cough drug, & Corbus’ disappointment

Young blood, supply chains, & an Operation Warp Speed gut check